Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 2,915 |
|
|||||
| News | - | ||||||
| Day High | 10.50 | Low High |
|||||
| Day Low | 10.40 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Instill Bio Inc | TIL | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.015 | 0.14% | 10.49 | 11:09:09 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.40 | 10.40 | 10.50 | 10.475 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 58 | 2,915 | US$ 10.49 | US$ 30,590 | - | 6.07 - 14.00 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 11:09:09 | 38 | US$ 10.49 | USD |
Instill Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 68.23M | 6.50M | - | 0 | -156.09M | -24.00 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Instill Bio News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/21/2024 | 16:00 | GlobeNewswire Inc. | Instil Bio Reports Fourth Quarter and Full Year 2023.. |
| 2/14/2024 | 15:08 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/13/2024 | 16:36 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 1/18/2024 | 06:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/16/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/16/2024 | 07:00 | GlobeNewswire Inc. | Instil Bio Announces Strategic Update |
| 1/10/2024 | 19:10 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 1/10/2024 | 18:49 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 12/08/2023 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/05/2023 | 16:00 | GlobeNewswire Inc. | Instil Bio Announces Effective Date of 1-for-20 Reverse.. |
| 11/27/2023 | 06:13 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/13/2023 | 16:27 | Edgar (US Regulatory) | Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TIL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 10.76 | 10.78 | 10.15 | 10.50 | 10,074 | -0.27 | -2.51% |
| 1 Month | 10.50 | 11.23 | 10.15 | 10.66 | 10,431 | -0.01 | -0.10% |
| 3 Months | 11.78 | 12.98 | 10.15 | 11.49 | 14,454 | -1.29 | -10.95% |
| 6 Months | 7.20 | 12.98 | 6.07 | 7.30 | 141,983 | 3.29 | 45.69% |
| 1 Year | 12.854 | 14.00 | 6.07 | 9.59 | 339,793 | -2.36 | -18.39% |
| 3 Years | 389.00 | 473.60 | 6.07 | 107.96 | 509,711 | -378.51 | -97.30% |
| 5 Years | 540.00 | 589.80 | 6.07 | 118.54 | 505,812 | -529.51 | -98.06% |
Instill Bio Description
| Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. |
